Momenta Pharmaceuticals has begun dosing in a Phase 1/2 clinical trial of M402 with gemcitabine in patients with advanced metastatic pancreatic cancer.
Lux Biosciences Inc. has completed patient enrollment in its Phase 3 clinical study using voclosporin for the treatment of non-infectious uveitis.
Inspiration Biopharmaceuticals Inc. reported data on the efficacy of OBI-1for the treatment of serious bleeds in people with acquired hemophilia A.
StemCells Inc. has initiated a Phase 1/2 clinical trial of HuCNS-SC in dry age-related macular degeneration, referred to as geographic atrophy.
Idenix Pharmaceuticals Inc. announced results from an ongoing Phase 2b study of IDX184 in combination with pegylated interferon and ribavirin.
Argos Therapeutics Inc. announced the approval of the revised special protocol assessment for its Phase 3 clinical study of AGS-003 for renal cell carcinoma.
Merck announced that a late-stage trial assessing Erbitux in combination with cisplatin and capecitabine for adenocarcinoma did not meet its primary endpoint.
InDex Pharmaceuticals announced the publication of positive data from the company's compassionate use program with its lead compound Kappaproct.
e-Therapeutics plc has started a Phase 1 clinical trial of ETS2101 as a cancer treatment, enrolling patients with primary brain cancer or cancer that has spread to the brain.
NOXXON Pharma has treated the first patient in a Phase 2a clinical trial of its anti-CCL2/MCP-1 Spiegelmer NOX-E36 in patients with diabetic nephropathy.
Infinity plans to initiate a Phase 2 trial of IPI-145 in patients with asthma, as well as a Phase 2 trial of IPI-145 in patients with rheumatoid arthritis in the second half of 2012.
Anthera Pharmaceuticals Inc. said its experimental lupus treatment blisibimod failed in a clinical trial, and changed its development plans for the drug.
ProtAffin AG announced that it has started dosing healthy volunteers in a Phase 1 clinical trial with its investigational anti-inflammatory, PA401.
3SBio Inc. has received approval from the State Food and Drug Administration to conduct a multi-center Phase 3 trial of voclosporin in China.
Iroko Pharmaceuticals announced Phase 3 study results showing patients treated with diclofenac experienced significant pain relief post-surgery compared with placebo.
Ventrus Biosciences Inc. announced that its most advanced drug failed in two late-stage clinical trials. Ventrus said ifanserin did not work better than a placebo.
The 2012 IntraLinks Global Investigator Site Survey revealed an increased prevalence in the use of online tools from 2011 to 2012, but that there is a significant opportunity for investigator sites to improve efficiency through web-based solutions for clinical trial exchange.
Medical Research Network has unveiled the deployment of its new patient scheduling tool to manage, report, and track clinical trial projects in real time.
Transition Therapeutics announced that TT-401, a type 2 diabetes drug, showed an acceptable safety profile in non-diabetic obese subjects in a Phase 1 study.
Genta has has reached an agreement with the U.S. Food and Drug Administration under its SPA process for a proposed Phase 3 trial of oral tesetaxel.
Genentech announced that patients with HER2-positive metastatic breast cancer lived significantly longer when treated with the combination of Perjeta, Herceptin, and docetaxel.
The University of Washington has begun enrolling patients in a Phase 2 study testing Cell Therapeutics' tosedostat in elderly patients with acute myeloid leukemia.
Raptor Pharmaceutical Corp. has finished enrollment for its Phase 2/3 clinical trial of RP103 for the potential treatment of Huntington's disease.
Hepatitis C drug developer Idenix Pharmaceuticals Inc. has reported promising results from a mid-stage study of a potential treatment.